277 related articles for article (PubMed ID: 33927271)
1. Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies.
Ito M; Takino N; Nomura T; Kan A; Muramatsu SI
Sci Rep; 2021 Apr; 11(1):9322. PubMed ID: 33927271
[TBL] [Abstract][Full Text] [Related]
2. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.
Sen D; Gadkari RA; Sudha G; Gabriel N; Kumar YS; Selot R; Samuel R; Rajalingam S; Ramya V; Nair SC; Srinivasan N; Srivastava A; Jayandharan GR
Hum Gene Ther Methods; 2013 Apr; 24(2):104-16. PubMed ID: 23442071
[TBL] [Abstract][Full Text] [Related]
3. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
[TBL] [Abstract][Full Text] [Related]
4. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.
Li C; Diprimio N; Bowles DE; Hirsch ML; Monahan PE; Asokan A; Rabinowitz J; Agbandje-McKenna M; Samulski RJ
J Virol; 2012 Aug; 86(15):7752-9. PubMed ID: 22593151
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
Li C; Narkbunnam N; Samulski RJ; Asokan A; Hu G; Jacobson LJ; Manco-Johnson MJ; Monahan PE;
Gene Ther; 2012 Mar; 19(3):288-94. PubMed ID: 21697954
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a Bioengineered AAV3B Capsid Variant with Enhanced Hepatocyte Tropism and Immune Evasion.
Rana J; Marsic D; Zou C; Muñoz-Melero M; Li X; Kondratov O; Li N; de Jong YP; Zolotukhin S; Biswas M
Hum Gene Ther; 2023 Apr; 34(7-8):289-302. PubMed ID: 36950804
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
[TBL] [Abstract][Full Text] [Related]
8. Successful liver transduction by re-administration of different adeno-associated virus vector serotypes in mice.
Baatartsogt N; Kashiwakura Y; Hiramoto T; Hayakawa M; Kamoshita N; Ohmori T
J Gene Med; 2023 Aug; 25(8):e3505. PubMed ID: 36972408
[TBL] [Abstract][Full Text] [Related]
9. Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.
Perocheau DP; Cunningham S; Lee J; Antinao Diaz J; Waddington SN; Gilmour K; Eaglestone S; Lisowski L; Thrasher AJ; Alexander IE; Gissen P; Baruteau J
Hum Gene Ther; 2019 Jan; 30(1):79-87. PubMed ID: 30027761
[TBL] [Abstract][Full Text] [Related]
10. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
Giles AR; Govindasamy L; Somanathan S; Wilson JM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
[TBL] [Abstract][Full Text] [Related]
12. Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.
Gabriel N; Hareendran S; Sen D; Gadkari RA; Sudha G; Selot R; Hussain M; Dhaksnamoorthy R; Samuel R; Srinivasan N; Srivastava A; Jayandharan GR
Hum Gene Ther Methods; 2013 Apr; 24(2):80-93. PubMed ID: 23379478
[TBL] [Abstract][Full Text] [Related]
13. Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach.
Havlik LP; Simon KE; Smith JK; Klinc KA; Tse LV; Oh DK; Fanous MM; Meganck RM; Mietzsch M; Kleinschmidt J; Agbandje-McKenna M; Asokan A
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669336
[TBL] [Abstract][Full Text] [Related]
14. Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy.
Kashiwakura Y; Endo K; Ugajin A; Kikuchi T; Hishikawa S; Nakamura H; Katakai Y; Baatartsogt N; Hiramoto T; Hayakawa M; Kamoshita N; Yamazaki S; Kume A; Mori H; Sata N; Sakata Y; Muramatsu SI; Ohmori T
Mol Ther Methods Clin Dev; 2023 Sep; 30():502-514. PubMed ID: 37693948
[TBL] [Abstract][Full Text] [Related]
15. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
[TBL] [Abstract][Full Text] [Related]
16. Successful AAV8 readministration: Suppression of capsid-specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease.
Choi SJ; Yi JS; Lim JA; Tedder TF; Koeberl DD; Jeck W; Desai AK; Rosenberg A; Sun B; Kishnani PS
J Gene Med; 2023 Aug; 25(8):e3509. PubMed ID: 36994804
[TBL] [Abstract][Full Text] [Related]
17. Superior human hepatocyte transduction with adeno-associated virus vector serotype 7.
Shao W; Pei X; Cui C; Askew C; Dobbins A; Chen X; Abajas YL; Gerber DA; Samulski RJ; Nichols TC; Li C
Gene Ther; 2019 Dec; 26(12):504-514. PubMed ID: 31570819
[TBL] [Abstract][Full Text] [Related]
18. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
[TBL] [Abstract][Full Text] [Related]
19. Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid.
Vercauteren K; Hoffman BE; Zolotukhin I; Keeler GD; Xiao JW; Basner-Tschakarjan E; High KA; Ertl HC; Rice CM; Srivastava A; de Jong YP; Herzog RW
Mol Ther; 2016 Jun; 24(6):1042-1049. PubMed ID: 27019999
[TBL] [Abstract][Full Text] [Related]
20. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets.
Wang L; Figueredo J; Calcedo R; Lin J; Wilson JM
Hum Gene Ther; 2007 Mar; 18(3):185-94. PubMed ID: 17324107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
